Skip to main content
Terug
HUM logo

Humana Inc.

Datakwaliteit: 100%
HUM
NYSE Healthcare Medical - Healthcare Plans
€ 170,14
▲ € 0,24 (0,14%)
Marktkapitalisatie: 20,52B
Dagbereik
€ 166,53 € 173,58
52-Weeksbereik
€ 163,11 € 315,35
Volume
1.290.831
50D / 200D Gem.
€ 204,15 / € 245,83
Vorige Slotkoers
€ 169,90

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (626 peers)

Metriek Aandeel Sector Mediaan
P/E 17,3 0,4
P/B 1,2 2,9
ROE % 7,0 3,7
Net Margin % 0,9 3,9
Rev Growth 5Y % 11,6 10,0
D/E 0,7 0,2

Koersdoel Analisten

Hold
€ 235,00 +38.1%
Low: € 146,00 High: € 345,00
Forward K/W
18,5
Forward WPA
€ 9,22
WPA Groei (sch.)
+0,0%
Omzet Sch.
160 B

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2030 € 41,63
€ 34,72 – € 45,09
 200 B 5
FY2029 € 38,84
€ 32,40 – € 42,06
 190 B 2
FY2028 € 26,37
€ 18,73 – € 35,68
 180 B 7

Belangrijkste Punten

Revenue grew 11,58% annually over 5 years — strong growth
Generating 375,00M in free cash flow
Capital efficient — spends only 0,42% of revenue on capex
ROIC of 3,56% — low return on invested capital

Groei

Revenue Growth (5Y)
11,58%
Revenue (1Y)10,06%
Earnings (1Y)-1,57%
FCF Growth (3Y)-64,51%

Kwaliteit

Return on Equity
6,98%
ROIC3,56%
Net Margin0,92%
Op. Margin1,12%

Veiligheid

Debt / Equity
0,73
Current Ratio0,72
Interest Coverage2,30

Waardering

P/E Ratio
17,27
P/B Ratio1,16
EV/EBITDA20,13
Dividend Yield0,01%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 10,06% Revenue Growth (3Y) 10,37%
Earnings Growth (1Y) -1,57% Earnings Growth (3Y) -30,91%
Revenue Growth (5Y) 11,58% Earnings Growth (5Y) -20,22%
Profitability
Revenue (TTM) 129,66B Net Income (TTM) 1,19B
ROE 6,98% ROA 2,44%
Gross Margin 14,54% Operating Margin 1,12%
Net Margin 0,92% Free Cash Flow (TTM) 375,00M
ROIC 3,56% FCF Growth (3Y) -64,51%
Safety
Debt / Equity 0,73 Current Ratio 0,72
Interest Coverage 2,30 Dividend Yield 0,01%
Valuation
P/E Ratio 17,27 P/B Ratio 1,16
P/S Ratio 0,16 PEG Ratio -18,57
EV/EBITDA 20,13 Dividend Yield 0,01%
Market Cap 20,52B Enterprise Value 29,26B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 129,66B 117,81B 106,44B 92,92B 83,65B
Net Income 1,19B 1,21B 2,49B 2,81B 2,93B
EPS (Diluted) 9,84 9,98 20,00 22,08 22,67
Gross Profit 18,85B 17,15B 18,05B 17,23B 14,45B
Operating Income 1,45B 1,63B 3,32B 3,56B 3,42B

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 48,75B 46,31B 46,89B 43,73B 44,75B
Total Liabilities 31,01B 29,87B 30,57B 28,36B 28,65B
Shareholders' Equity 17,66B 16,38B 16,26B 15,31B 16,08B
Total Debt 12,94B 12,26B 12,27B 11,75B 13,23B
Cash & Equivalents 4,20B 2,22B 4,69B 5,06B 3,39B
Current Assets 7,47B 4,93B 6,73B 6,74B 5,21B
Current Liabilities 10,31B 11,26B 11,95B 11,63B 10,49B

Strategiescores

This stock passed the criteria for 1 strategy

Score = fit strength (0–100)
Rank = position among all matches
Growth Price/Sales Ratio Focus (Ken Fisher)
#474 of 616
18

Recente Activiteit

Ingestapt Price/Sales Ratio Focus (Ken Fisher)
Mar 24, 2026